1. Best quarterly revenue so far of ₹562.8Cr compared to ₹435.7Cr in Q2 FY22and ₹384.8Cr in Q3 FY21. 2. Y-o-Y growth of 46.2% and sequential growth of 29.2% in revenue.
3. Gross Profit of ₹118.5Cr in Q3 FY21-22 compared to ₹92.3Cr in Q2 FY22. 4. Y-o-Y growth of 70.9% and sequential growth of 28.5% in Gross Profit. 5. Gross Profit margin expanded from 18.0% in Q3FY21 to 21.1% in Q3 FY22.
6. Ebitda of ₹77.2Cr in Q3 FY22 compared to ₹61.7Cr in Q2 FY22 and ₹44.5Cr in Q3 FY21 7. Y-o-Y growth of 73.5% and sequential growth of 25.2% in Ebitda. 8. Ebitda Margins of 13.7% in Q3 FY22 compared to 14.2% in Q2 FY22.
9. Adjusted Profit After Tax of ₹596mn in Q3 FY21-22 compared to ₹454mn in Q2 FY22. 10. Adjusted Profit After Tax margin of 10.6% in Q3 FY22 compared to 10.4% in Q2 FY22.
11. Adjusted for ESOP benefit expenses (net of tax) and non-cash amortization associated with the intangible assets added as a result of purchase price allocation for acquisitions
12. Interim dividend of ₹3 per share approved by the Board of Directors.
Net cash as of 31st December 2021 is ₹1103.6 Cr.
Business Update
1. Company raised ₹ 867.5Cr through Qualified Institutional Placement (‘QIP’) in Nov’21 from several global marquee investors.
This QIP money will be utilized to accelerate organic & inorganic growth.
2. Company launched their Payment as a Service offering, which provides 360°seamless payment experience, multiple Payment gateways and integration with UPI.
3. Company was recognized as an ESG leader based on its strength in data privacy & security, community support & development, board independence and ethical business practices.
4. Company conducted a global API hackathon which had participation of more than 7000+ developers.
5. Company incurred a capex of 12Cr last quarter. Large part of Capex was towards a new call center facility that has been setup, 5-6Cr was used for that and the remaining was used for infrastructure upgradation.
6. Company completed the acquisition of 100% equity in Masivian S.A.S (“Masiv”), on November 11, 2021.Masiv’s differentiated cloud communication platform offerings for enterprises create a springboard for growth in Latin America
7. Total purchase consideration, including adjustments and earnout, of US $51.3mn (₹381.3Cr) ~63.16% paid upon closing while the second, third and fourth instalments, each equivalent to 12.28% will be paid upon completion of 12, 18 and 24 months from the date of closing.
8. Company also acquired a 49% equity stake and 90% economic and beneficial interest in Interteleco on 1st December 2021.
Total purchase consideration of KWD 652,500 (₹16.3Cr).
These acquisitions will enhance their operator relationships and help with their enterprise segment growth in both regions i.e Latin America and Kuwait.
9. Company has already set up sales offices in Mexico, Chile & Peru to capture the Latin America market.
10. Average realization from billable transactions decreased from 40 pesos in Q2FY22 to 35 pesos in Q3FY22 owing to lower average realization per billable transaction in masivian and lower email average realization.
11. Billable transactions increased from 8.82B in Q3FY21 and 10.86B in Q2 FY22 to 16.29B in Q3FY22. This includes a 3.31B billable transaction by Masivian & Interteleco.
12. Company added 250+ new customers in 9M period
13. Company onboarded 150+ new employees during the 9M period.
14. Attrition rate increased from 11% in FY21 to 20% in 9m FY22 on an annualized basis.
15. For 9M FY22, ESOP benefit expenses (non cash) were adjusted from EBITDA amounting to ₹9.3Cr.
16. Masivian gross margins are 40% and there is room to grow.
17. Interteleco gross margins are around 20%.
18. Company’s organic growth QoQ was up 22% and had all time high growth. Indian business continues to grow.
Future Outlook
1. Company’s vision is to focus on the global market and the company will look for acquisitions with the idea of expansion.
2. Company expects Q4 FY22 to be good.
3. Company did 27.7Cr of revenue from their products and company believes that revenue from product can be 2x,3x in coming years.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
1. Revenue growth was at 6%. EBITDA margins were at 22.7% which tracks with their full year guidance despite increased RM and freight costs.
The cost increases were offset by increased share of the complex and chronic launches, continuous rigor on cost control and operating efficiencies.
2. One India reported 13% growth YoY. The core prescription business in India excluding COVID grew strongly by 16% YoY. The branded prescription business is on track to achieve the $1 Billion mark
1. Revenues from operations stood at ₹394 Cr in Q3FY21 with gross margins at 26.64% and EBITDA margins at 15.32%
2. The rise in input cost was overcome as a result of cost improvement.
3. Addition of ₹2.2Cr one time exceptional expense for Mahad overflooded facility
Insurance claims are expected and will be reflected in March FY23
4. Fourth quarter is expected to be much better.
5. Galaxmusk and camphor are huge volume products and will be sold initially in the spot market as most of the requirement by customers is in the second half.Volumes will be reflected in next few quarter as top 25 clients enter annual contracts
1. Revenue for the quarter was ₹5320 Cr ($715 million). Growth of 8% YoY and declined 8% sequentially. YoY growth is due to good performance across all segments.
2. Sequential decline due to high base in Q2 which had a higher contribution from COVID related products.
3. Gross Profit margin for the quarter was 53.8%, increase of 40 bps QoQ. Gross margins for Global Generics were at 57.8% and PSAI were 22.5%.
4. SG&A spend for the quarter was ₹1541 Cr ($207 million). Increase of 7% YoY and decline of 3% QoQ. YoY increase is due to business expansion and increased spend on sales and marketing activities.
Financial Updates - 1. The Revenue for Q3 were up by 33% at 508 cr 2. The companies gross margins are at 60% and has increased 39% YoY
3. EBITDA margins stood at 26.2% grew at 37% YoY, PAT grew by 25% YoY 4. The ARR (Annual Recurring Revenue) stood ar 683 cr 5. The Collection in Q3 were 485 cr, Collection days / DSO stood at 129 days 6. The company has zero debt and cash stands at 431 cr as of Dec 21.
7. SaaS Subscription revenue is up by 113% YoY at 89 cr 8. Licenses revenue is up by 23% YoY at 112cr 9. AMC stood at 82 cr, grew 11% YoY 10. On YTD basis 57% of the revenues are license linked and 43% is Implementation revenue.
1. The revenue for Q3 was 143.4 Million dollars up by 4.7%QoQ and 20.1% YoY
2. The TCV of the deal wins in Q3 was 185 million dollars, the new business contributing about 121 million dollars, The year to date TCV stood at 474 million dollars. 3. The Enterprise business was up by 6.1% QoQ and 81% YoY
4. Business technology and transformation was up by 4.4% QoQ and 31% YoY 5. Cloud based services was up by 2.7% QoQ and 29%YoY 6. The manufacturing vertical was up by 9% QoQ and 20% YoY 7. Energy and utilities was up by 8.4% QoQ and 20.2% YoY
1. Apollo Pharmacies has signed an agreement with Amazon to list their pharmacy products on amazon.in
2. Apollo already has its own healthcare platform called Apollo 24/7 which offers secure on-line consults, consultation bookings and medicine orders from an Apollo Pharmacy close to their home for delivery at their doorstep in two hours.
Apollo 24/7 has over 30 million registered users.
3. Their omnichannel network generates over 200 million prescriptions annually. With Amazon’s partnership they intend to grow this by 50% over the next 2 years.